Extended Data Fig. 8: De novo development of different genetic alterations between paired primary and metastatic sites by cancer type.

Percentage of patients with paired primary and metastatic samples demonstrating de novo mutations in antigen presenting mechanism (APM) genes, including B2M, TAP1, TAP2, HLA-A, HLA-B, and HLA-C. All samples were filtered to ensure a sample purity of greater than 20%.